76 episodes
Ep. 124 - Texas Medical Center’s William McKeon on making Texas the U.S. pilot for faster trials
13/11/2026 | 33 mins.Texas Medical Center CEO William McKeon wants Texas to serve as the U.S. pilot for faster, cheaper clinical trials. In an interview with BioCentury Editor in Chief Simone Fishburn on The BioCentury Show, McKeon described how TMC’s centralized IRB gives sponsors a single approval covering 10 million patients, and his push to extend it statewide. He also discussed competition from China, Australia and Spain for early-stage trials and a proposed Australia-style refundable R&D tax credit for the upcoming Texas legislative session. This episode of The BioCentury Show has been brought to you by Tigermed.
View full story: https://www.biocentury.com/article/661560
#ClinicalTrials #LifeSciences #HealthPolicy #Texas #ClinicalResearch
0:00 Introduction
01:15 TMC in a Nutshell
11:57 A Model for the U.S.
15:23 Competing with China
18:46 Policy Proposals: Tax Credit
27:47 Embedding Trials in CareEp. 123 - Gilde’s Joep Muijrers on why patients belong in the investment process
30/10/2026 | 33 mins.On this edition of The BioCentury Show, Gilde's Joep Muijrers joins BioCentury’s Stephen Hansen to discuss how the firm’s Impact Council of former regulators, payers, HTA leaders, and patient advocates shapes its investment decisions. Muijrers explains how council input steered Gilde away from one deal and toward another, diagnostics company Karius, and why he argues patient perspectives belong alongside physician input in diligence and development strategy. He also describes the frameworks Gilde has developed for engaging patient organizations, and why he urges other investors to adopt them as a pre-competitive practice. This episode of The BioCentury Show is brought to you by Tigermed.
View full story: https://www.biocentury.com/article/661356
#PatientEngagement #BiotechInvesting #ImpactInvesting #VentureCapital #MarketAccess
0:00 Introduction
2:00 Creating Gilde's Impact Council
7:32 Advisors' Impact on Investing
16:42 Gilde's Approach to Patient Engagement
23:50 Where Patient Input Fits in Decision-making
29:17 Why Other Investors Should EngageEp. 122 - Tigermed's Britney Winterberger's take on running trials in the U.S. and China
21/10/2026 | 29 mins.Tigermed, the largest clinical CRO in China, has expanded into more than 50 countries and is growing its North American operations, offering full-service support from preclinical through Phase IV. On this sponsored edition of The BioCentury Show, Britney Winterberger, Tigermed’s VP and head of North America clinical operations, tells BioCentury Executive Editor Jeff Cranmer how the CRO helps U.S. sponsors run trials in China and Chinese sponsors run trials in the U.S. — and why combining both in a single protocol can de-risk FDA acceptance while capturing China’s enrollment speed. Winterberger also discusses investigator-initiated trials in China, China’s new IIT regulations, and trial trends spanning bispecifics, ADCs, cell and gene therapies, and radiopharmaceuticals.
This episode of The BioCentury Show is brought to you by Tigermed.
View full story: https://www.biocentury.com/article/661260
#GlobalClinicalTrials #IITs #Oncology #ADCs #CRO
0:00 Introduction
1:17 Tigermed's Global Capabilities
2:59 Running Trials in China
7:05 Chinese Sponsors in the U.S.
16:42 IITs
22:28 Trends in Trial Design- Arrowhead Pharmaceuticals can now deliver siRNA to seven cell types, and new data showing subcutaneous delivery to the brain could push RNAi therapies well beyond the liver. On this edition of The BioCentury Show, Arrowhead Chairman, President, and CEO Chris Anzalone joins BioCentury’s Stephen Hansen to discuss where siRNA has the edge over ASOs, what the Phase III miss for Novartis’ pelacarsen means for olpasiran, the Lp(a) therapy Arrowhead partnered with Amgen, and the growth outlook for plozasiran in severe hypertriglyceridemia. Anzalone also describes Arrowhead’s obesity programs targeting INHBE and ALK7, and a dimer molecule that silences two genes at once.
View full story: https://www.biocentury.com/article/661194
#RNAi #siRNA #DrugDelivery #DrugDevelopment #Biotech
0:00 Introduction
1:09 Arrowhead's siRNA Platform
9:05 Solving for Extra-Hepatic Delivery
23:43 Redemplo's Future Growth
27:00 Obesity and Bispecific siRNA - Untapped multibillion-dollar markets are hiding in plain sight where patients endure mediocre generic standards of care, according to Canaan General Partner Julie Grant, co-founder and first CEO of Day One, which Servier acquired for $2.5 billion this year. In an interview with BioCentury's Lindsay Martin, Grant discussed white spaces in women's health such as migraine and anemia, and why mid-tier acquirers like Jazz, Ipsen and Servier make smaller markets viable. She also explained why the last private round can understate value by 10-20X, how Canaan builds management teams around a key individual who sets the tone and why biotech needs scientific heroes as AI captures most venture dollars.
View full story: https://www.biocentury.com/article/660963
#VentureCapital #Biotech #WomensHealth #DrugDevelopment #BiotechMA
0:00 Introduction
1:19 Canaan's Strategy
11:34 Team Building
21:57 White Space
28:00 New Biotech Buyers
34:15 Biotech Founders
More Business podcasts
Trending Business podcasts
About The BioCentury Show
Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.Don't miss this event, every two weeks, now available as a video webcast or audio podcast.
Podcast websiteListen to The BioCentury Show, Merryn Talks Money and many other podcasts from around the world with the radio.net app

Get the free radio.net app
- Stations and podcasts to bookmark
- Stream via Wi-Fi or Bluetooth
- Supports Carplay & Android Auto
- Many other app features
The BioCentury Show: Podcasts in Family









































